Jazz Pharmaceuticals plc

NASDAQ:JAZZ   3:59:50 PM EDT
140.54
-0.16 (-0.11%)
Products, Regulatory

Jazz Pharmaceuticals And Pharmamar Announce Results Of Atlantis Phase 3 Study Evaluating Zepzelca™ In Combination With Doxorubicin For Patients With Small Cell Lung Cancer

Published: 12/03/2020 07:20 GMT
Jazz Pharmaceuticals plc (JAZZ) - Jazz Pharmaceuticals and Pharmamar Announce Results of Atlantis Phase 3 Study Evaluating Zepzelca™ in Combination With Doxorubicin for Patients With Small Cell Lung Cancer Following One Prior Platinum-containing Line.
Jazz Pharmaceuticals-study Did Not Meet Pre-specified Criteria of Significance for Primary Endpoint of Overall Survival in Intent-to-treat Population.
Jazz Pharmaceuticals-study Did Not Meet Pre-specified Criteria of Significance for Primary Endpoint of Os Comparing Lurbinectedin in Combination With Doxorubicin to Control Arm.
Jazz Pharmaceuticals Plc - There Was No Adverse Effect on Os With Experimental Arm.
Jazz Pharmaceuticals Plc - Based on Study Design, No Additional Hypotheses Were Formally Tested.
Jazz Pharmaceuticals Plc - Safety Data in Was Consistent With Known Safety Profile of Lurbinectedin Monotherapy With No New Safety Signals Observed.
Jazz Pharmaceuticals Plc - Lurbinectedin Monotherapy Was Not Tested in Atlantis.